Accueil / Tag Archives: FDA

Tag Archives: FDA

Ipsen Announces FDA Approval of Dysport® (Abobotulinumtoxina) for the Treatment of Lower Limb Spasticity in Adults

Friday, June 16th 2017 at 4:00pm UTC Spasticity may affect adults who suffer from stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, and cerebral palsy PARIS–(BUSINESS WIRE)– class= »bwalignl »> Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen) today announced that the U.S. Food and Drug Administration (FDA) has expanded the …

Plus »

Advaxis to Present at 2017 BIO International Convention

Friday, June 16th 2017 at 12:00pm UTC PRINCETON, N.J.–(BUSINESS WIRE)– Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that Ranya Dajani, Vice President, Business Development, will present a company overview at the 2017 Biotechnology Innovation Organization’s (BIO) International Convention in San Diego, CA. Event: 2017 …

Plus »

ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue™ Therapy for the Treatment of Local Anesthetic Systemic Toxicity

Thursday, June 15th 2017 at 10:05pm UTC On Track to File New Drug Application (NDA) in First Half of 2018 and Currently in Discussions and Soliciting Potential Commercialization Partners CHICAGO–(BUSINESS WIRE)– ResQ Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) …

Plus »

Ipsen annonce que la FDA a approuvé l’autorisation de mise sur le marché du Dysport® (abobotulinumtoxinA) pour le traitement de la spasticité des membres inférieurs chez l’adulte

Friday, June 16th 2017 at 4:00pm UTC La spasticité peut concerner les adultes souffrant d’un accident vasculaire cérébral, d’un traumatisme crânien, d’une lésion médullaire, d’une sclérose en plaques et d’une infirmité motrice cérébrale PARIS–(BUSINESS WIRE)– class= »bwalignl »> Regulatory News: Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd’hui que les autorités réglementaires …

Plus »

Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults

Friday, June 16th 2017 at 5:18pm UTC Spasticity may affect adults who suffer from stroke, traumatic brain injury, spinal cord injury, Multiple Sclerosis, and Cerebral Palsy BASKING RIDGE, N.J.–(BUSINESS WIRE)– Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and …

Plus »

Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017

Thursday, June 15th 2017 at 12:00pm UTC — Abstracts Report on Screening Population for PALISADE Phase 3 Clinical Trial and Current Management of Peanut Allergy — BRISBANE, California–(BUSINESS WIRE)– Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, announced today that it will present data during …

Plus »

Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017)

Wednesday, June 14th 2017 at 10:59am UTC Key analyses focus on treatment outcomes among RA patients with a traditionally poor prognosis ORENCIA® (abatacept) continuing research underscores Bristol-Myers Squibb’s commitment to advancing the science of modulating the body’s immune response to treat disease PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE:BMY) today …

Plus »

Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations

Wednesday, June 14th 2017 at 11:30am UTC Will oversee Biogen’s worldwide commercial operations outside the U.S. CAMBRIDGE, Mass.–(BUSINESS WIRE)– Biogen (NASDAQ: BIIB) announced today the appointment of Jean-Paul Kress, MD, as Executive Vice President and President, International, and Head of Global Therapeutic Operations, effective June 19. Dr. Kress will have …

Plus »

Humacyte® Selected as 2017 Technology Pioneer by World Economic Forum

Wednesday, June 14th 2017 at 5:00pm UTC Humacyte was selected for potential to significantly impact business and society through new technologies in regenerative medicine RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Humacyte, an innovator in biotechnology and regenerative medicine, was selected among hundreds of candidates as one of the World Economic Forum’s …

Plus »
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE !
Vous appréciez cet article ? Faites-nous part de vos commentaires.
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cuZWVpLWJpb3RlY2hmaW5hbmNlcy5jb20vd3AtY29udGVudC91cGxvYWRzLzIwMTUvMDcvU2F0cmEtMi5tcDQiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...